Dr. Renschler is President and Chief Executive Officer of Cyteir Therapeutics and has led the company from discovery stage to clinical stage. He is a biotech entrepreneur experienced in building successful cancer companies, as well as a medical oncologist with 25 years’ experience in cancer research from basic laboratory research to drug approval and drug launches. He has been in leading roles in clinical R&D, project leadership, business development, and medical affairs at Celgene, Pharmion, and Pharmacyclics, with responsibility for successful global registrations in breast cancer, non-small cell lung cancer, and pancreatic cancer, as well as the medical strategy for drug launches in hematologic malignancies and solid tumors for drugs such as lenalidomide, pomalidomide, nab-paclitaxel, and azacitidine. Dr. Renschler was a post-doctoral fellow with Dr. Ronald Levy at Stanford University, working on patient-specific vaccines and antibody treatments for Non-Hodgkin lymphoma. He is a board certified medical oncologist with an MD from Stanford University and BA from Princeton University. Dr. Renschler was an Adjunct Clinical Associate Professor of Medicine (Oncology) at Stanford University until 2015, where he was teaching and treating patients in the lymphoma program.
